Views & Analysis | Perspectives on pharma industry issues

Oncology

On GDF-15 neutralisation and cachexia, with CatalYm

As ESMO 2026 continues to get underway, pharmaphorum web editor Nicole Raleigh spoke with Scott Clarke, CEO of CatalYm.

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Articles

CME in Europe: doctors’ perspectives and patient outcomes

Michelle Kelly discusses the topic of European CME, looking at HCP participation, views and preferences. Last month, thought-leaders and stakeholders of Continuing Medical Education (CME) convened at the...

Articles

KOL perspectives: Professor Peter Fitzgerald

In this interview we speak with KOL Professor Peter Fitzgerald of Stanford University School of Medicine Health Sciences on his thoughts on a successful industry / KOL relationship in the cardiovascular technology landscape. In this new series we seek to hear KOL’s perspectives on how they think they could best work with the pharma industry...

Articles

A roundup of ‘physician perspectives’ from 2012

pharmaphorum takes a look at the combined social media messages in all the physician perspectives interviews from 2012. In the past year, we’ve spoken with a number of leading physicians who are advocates of social media. As we near the...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital